PFIZER INC SEC 10-K Report

robot
Abstract generation in progress

Pfizer Inc. has released its 2025 Form 10-K report, detailing a 2% decrease in total revenues to $62.6 billion, primarily due to operational declines, with reported diluted EPS at $1.36 and adjusted diluted EPS up by 4% to $3.22. The report highlights strategic initiatives focused on R&D, market leadership, and cost realignment, while addressing significant challenges including pricing pressures, competition, patent expirations, and geopolitical risks. Pfizer aims to maximize key transactions, achieve R&D milestones, and invest in post-2028 growth, along with committing to net-zero emissions by 2040.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский язык
  • Français
  • Deutsch
  • Português (Portugal)
  • ภาษาไทย
  • Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)